Sarcoidosis: Immunopathogenesis and the potential of immunotherapy;Sarcoïdose: Immunopathogenese en aanknopingspunten voor immunotherapie

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 4, 2003, Pages 150-155

  Gras, M ^a   Van Kemenade, F J ^a   Van Maarsseveen, A C M Th ^a   Alberts, C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYTOKINE; CYTOSTATIC AGENT; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CYTOKINE PRODUCTION; GRANULOMATOUS INFLAMMATION; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATORY CELL; MACROPHAGE; SARCOIDOSIS;

EID: 0037464801     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). Am J Respir Crit Care Med 1999;160:736-55.
2. Sharma OP. Sarcoidosis: clinical management. Londen: Butterworths; 1984. p. 22-8.
3. Maarsseveen ACMTh van, Mullink H, Alons C, Stam J. Distribution of T lymphocyte subsets in different portions of sarcoid granulomas: immuno-histological analysis by monoclonal antibodies. Human Pathol 1986;17:493-500.
4. Semenzato G, Agostini C. Immunology of sarcoidosis. In: Schwarz MI, King TE, editors. Interstitial lung disease. 2nd ed. St. Louis: Mosby Year Book; 1993. p. 127-58.
5. Müller-Quemheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Immunological review. Eur Respir J 1998;12:716-38.
6. Vourlekis JS, Sawyer RT, Newman LS. Sarcoidosis: developments in etiology, immunology, and therapeutics. Adv Intern Med 2000; 45:209-57.
7. Möllers M, Aries SP, Drömann D, Mascher B, Braun J, Dalhoff K. Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis. Thorax 2001;56:487-93.
8. Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996;156: 4952-60.
9. Shigehara K, Shijubo N, Ohmichi M, Takahashi R, Kon S, Okamura H, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001;166:642-9.
10. Hoffmann RM, Jung MC, Motz R, Gössl C, Emslander HP, Zachoval R, et al. Sarcoidosis associated with interferon-α therapy for chronic hepatitis C. J Hepatol 1998;28:1058-63.
11. Pietropaoli A, Modrak J, Utell M. Interferon-alpha therapy associated with the development of sarcoidosis. Chest 1999;116:569-72.
12. Agostini C, Adami F, Semenzato G. New pathogenic insights into the sarcoid granuloma. Curr Opin Rheum 2000;12:71-6.
13. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:121-30.
14. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999;54:742-6.
15. Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999;14:1117-22.
16. Baughman RP, Ohmichi M, Lower EE. Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:133-7.
17. James DG. Sarcoidosis 2001. Postgrad Med J 2001;77:177-80.
18. Tijhuis GJ, Putte LB van de, Breedveld FC. Behandeling van reumatoïde artritis door blokkade van tumornecrosisfactor met infliximab of etanercept. Ned Tijdschr Geneeskd 2001;145:1880-5.
19. Deventer SJH van. Inflammatoire darmziekten: pathogenetische aanknopingspunten voor specifieke therapie. Ned Tijdschr Geneeskd 1997;141:1956-9.
20. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000;119:1473-82.
21. Conroy CA, Cattell R. Infliximab treatment for Crohn's disease. Postgrad Med J 2001;77:436-40.
22. Hommes DW, Parlevliet W, Sterringa GJ, Hermans W, Bartelsman JFWM, Deventer SJH van. Toepassing van infliximab bij patiënten met de ziekte van Crohn; ervaringen bij 132 patiënten. Ned Tijdschr Geneeskd 2002;146:1187-91.
23. Yee AMF, Pochapin MP. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med 2001;135:27-31.
24. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4.